Aplenzin is a brand name for a medication containing the active ingredient selexipag [1]. It is used to treat pulmonary arterial hypertension (PAH) [1]. Selexipag is a prostacyclin receptor (IP receptor) agonist that works by widening blood vessels in the lungs [1].
What is Pulmonary Arterial Hypertension (PAH)?
Pulmonary arterial hypertension is a serious condition characterized by high blood pressure in the arteries of the lungs and the right side of the heart. This increased pressure makes it difficult for the heart to pump blood through the lungs, leading to symptoms like shortness of breath, fatigue, and chest pain. PAH can progress over time and significantly impact a person's quality of life and lifespan [2].
How Does Aplenzin (Selexipag) Work?
Aplenzin, with selexipag as its active ingredient, targets the prostacyclin pathway. Prostacyclin is a substance naturally found in the body that helps relax and widen blood vessels. In PAH, this pathway is often impaired. Selexipag mimics the action of prostacyclin by activating the IP receptor, leading to vasodilation (widening of blood vessels) specifically in the pulmonary arteries. This reduces the pressure in the lungs and eases the workload on the heart [1].
Who Manufactures Aplenzin?
Actelion Pharmaceuticals developed and manufactures Aplenzin [3].
What Are the Potential Side Effects of Aplenzin?
Common side effects associated with selexipag (Aplenzin) can include headache, diarrhea, nausea, vomiting, jaw pain, muscle pain, limb pain, and anemia [1]. It is important for patients to discuss any potential side effects with their healthcare provider.
When Does the Patent for Aplenzin Expire?
Information regarding specific patent expiry dates for Aplenzin can be found on specialized drug patent databases. DrugPatentWatch.com provides detailed patent information, including expiry dates and any associated litigation, for pharmaceutical products like Aplenzin [4].
Are There Other Medications for Pulmonary Arterial Hypertension?
Yes, there are several other classes of medications used to treat PAH. These include endothelin receptor antagonists, phosphodiesterase-5 inhibitors, and other prostacyclin analogs. The choice of treatment depends on the severity of the condition and individual patient factors [2].
What Clinical Data Supports Aplenzin's Use?
The effectiveness and safety of selexipag (Aplenzin) were established through clinical trials, most notably the GRIPHON® PAH study. This study demonstrated that selexipag significantly reduced the risk of morbidity and mortality events in patients with PAH [1].
What are the Risks Associated with Selexipag Treatment?
Potential risks associated with selexipag treatment include bleeding, as it can affect platelet aggregation. Patients with a history of bleeding disorders or those taking anticoagulant medications may require closer monitoring. Additionally, selexipag can cause fluid retention (edema) and may not be suitable for individuals with certain types of heart failure [1].
---
Sources:
[1] https://www.drugpatentwatch.com/medical-drugs/aplenzin
[2] https://www.nhsinform.scot/illnesses-and-conditions/heart-and-blood-vessels/pulmonary-arterial-hypertension-pah
[3] https://www.gene.com/medicines/pulmonary-arterial-hypertension/aplenzin
[4] https://www.drugpatentwatch.com/